Research programme: G protein-coupled receptor modulators - Arena Pharmaceuticals/Taisho Pharmaceutical

Drug Profile

Research programme: G protein-coupled receptor modulators - Arena Pharmaceuticals/Taisho Pharmaceutical

Alternative Names: ATC 0021; ATC 0044; ATC 0065; ATC 0175 (AR 224349); ATC 0453; ATC 0759; GPCR modulators - Arena/Taisho

Latest Information Update: 21 Mar 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arena Pharmaceuticals
  • Class Cyclohexylamines; Quinazolines; Small molecules
  • Mechanism of Action G protein-coupled receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anxiety disorders; Major depressive disorder; Obesity; Sleep disorders

Most Recent Events

  • 07 May 2008 A lead compound from this programme has entered clinical development
  • 07 Nov 2007 Pharmacodynamics data from Preclinical trials in Anxiety and Depression presented at the 37th Annual Meeting of the Society for Neuroscience (SFN-2007)
  • 16 Jun 2005 Preclinical trials in Anxiety disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top